The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jul. 04, 2023

Filed:

Mar. 12, 2018
Applicant:

Ucl Business Ltd., London, GB;

Inventors:

Thomas Voit, London, GB;

Julie Dumonceaux, London, GB;

Virginie Mariot, London, GB;

Assignee:

UCL Business Ltd., London, GB;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
G01N 33/68 (2006.01); A61K 38/17 (2006.01); G01N 33/74 (2006.01);
U.S. Cl.
CPC ...
G01N 33/6887 (2013.01); A61K 38/177 (2013.01); G01N 33/74 (2013.01); G01N 2800/52 (2013.01);
Abstract

The present invention provides a method for determining whether a patient will respond to treatment with a myostatin pathway inhibitor, the method comprising: (a) determining a level of myostatin and/or activin type II receptor (ActRII) and/or follistatin in at least one muscle biopsy obtained from a treatment target muscle in a subject having or suspected of having muscle atrophy or a muscle wasting condition; and (b) determining a level of myostatin and/or follistatin in a systemic sample obtained from the patient, wherein if: (i) the level of myostatin in the systemic sample is higher than a threshold and/or if the level of follistatin in the sample is lower than a threshold; and (ii) the level of myostatin and/or ActRII receptor in the at least one biopsy sample is higher than a threshold level and/or if the level of follistatin in the at least one biopsy sample is lower than a threshold level, the patient will respond to treatment.


Find Patent Forward Citations

Loading…